Conference: 2007 PH Resource Network Symposium
Release Date: 10.12.2007
Presentation Type: Breakout Sessions
File Download: 2007 Symposium Remodulin
Download Adobe Acrobat
New treatment options provide improved health outcomes for patients, but how do they compare with more established treatments? Intravenous and subcutaneous Remodulin (treprostinil), approved by the FDA in 2002, will be reveiwed and compared with the first of the prostacyclins, Flolan (epoprostenol). Specific challenges and solutions of IV and SQ Remodulin treatment will also be covered, such as line infections, site pain and transitions.